ReviewDiseases (Basel, Switzerland)2015
Systemic Chemotherapy for Advanced Hepatocellular Carcinoma: Past, Present, and Future.
Review in Diseases (Basel, Switzerland), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 55 citations in OpenAlex.
- Cathepsin Inhibitor Suppresses the Growth of Ectopic Hepatocellular Carcinoma Tumors in Mouse Models.ACS pharmacology & translational science · 2026Article
- Article
- The interplay between microRNAs and Nrf2 signaling in human cancers.Cancer cell international · 2024Review
- Anti-cancer effect of nano-encapsulated boswellic acids, curcumin and naringenin against HepG-2 cell line.BMC complementary medicine and therapies · 2023Article
- Safety and dose escalation of the targeted oncolytic adenovirus OBP-301 for refractory advanced liver cancer: Phase I clinical trial.Molecular therapy : the journal of the American Society of Gene Therapy · 2023Article
- Anatomical Targeting of Anticancer Drugs to Solid Tumors Using Specific Administration Routes: Review.Pharmaceutics · 2023Review
- TKIs beyond immunotherapy predict improved survival in advanced HCC.Journal of cancer research and clinical oncology · 2023Article
- The Role of Ablative Techniques in the Management of Hepatocellular Carcinoma: Indications and Outcomes.Biomedicines · 2023Review
- Systemic Therapy for Advanced Hepatocellular Carcinoma: Current Stand and Perspectives.Cancers · 2023Review
- Enhanced efficacy of direct immunochemotherapy for hepatic cancer with image-guided intratumoral radiofrequency hyperthermia.Journal for immunotherapy of cancer · 2022Article
- Drug Discovery Using Evolutionary Similarities in Chemical Binding to Inhibit Patient-Derived Hepatocellular Carcinoma.International journal of molecular sciences · 2022Article
- Differential expression of insulin-like growth factor type 1 receptor identifies heterogeneous intrahepatic regulatory T subsets in mouse hepatocellular carcinoma.Clinical and experimental immunology · 2022Article
- Lipid based nanoparticles as a novel treatment modality for hepatocellular carcinoma: a comprehensive review on targeting and recent advances.Journal of nanobiotechnology · 2022Review
- Diagnosis and prognosis models for hepatocellular carcinoma patient's management based on tumor mutation burden.Journal of advanced research · 2021Article
- Targeting Notch to Maximize Chemotherapeutic Benefits: Rationale, Advanced Strategies, and Future Perspectives.Cancers · 2021Review
- Recent Progress in Systemic Therapy for Hepatocellular Cancer (HCC).Current treatment options in gastroenterology · 2021Article
- MiniPDX-guided postoperative anticancer treatment can effectively prolong the survival of patients with hepatocellular carcinoma.Cancer chemotherapy and pharmacology · 2021Article
- PTEN inhibition leads to the development of resistance to novel isoquinoline derivative TNBG-5602 in human liver cancer cells.American journal of cancer research · 2021Article
- Hepatocellular Carcinoma: An Overview of the Changing Landscape of Treatment Options.Journal of hepatocellular carcinoma · 2021Review
- Circular RNAs and Hepatocellular Carcinoma: New Epigenetic Players With Diagnostic and Prognostic Roles.Frontiers in oncology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Systemic chemotherapy is one of the most important treatment modalities for advanced hepatocellular carcinoma (HCC). Before the introduction of sorafenib, cytotoxic agents, hormonal therapies, or many combinations of these were the mainly used modalities for systemic chemotherapy of advanced HCC. However, such regimens were of only limited value in clinical practice, because some randomized controlled studies comparing promising regimens with no treatment or doxorubicin alone failed to show any overall survival advantage. In two pivotal phase III placebo-controlled studies, the SHARP trial and the Asia-Pacific trial, sorafenib was demonstrated to significantly delay the time to progression and the overall survival time in patients with advanced HCC. Therefore, sorafenib therapy has come to be acknowledged as a standard therapy for advanced HCC worldwide. After the introduction of sorafenib, a number of phase III trials of various molecular-targeted agents
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.